Effects of intragastric Amarasate™ extract (bitter agonist), on upper gastrointestinal (GI) functions and energy intake in healthy, lean volunteers.

Professor Christine Feinle-Bisset0 个研究点目标入组 11 人开始时间: 2020年4月23日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•A total of 12 healthy, lean (BMI 19-25 kg/m2) male subjects, aged between 18 - 60 years will be included. Subjects will be required to be weight stable (ie <5% fluctuation) at study entry, which will be ascertained by a stable body weight in the preceding 4 weeks.

•Significant GI symptoms, disease or surgery
•Use of prescribed or non-prescribed medications (including vitamins and herbal Supplements) which may affect energy metabolism, GI function, body weight or appetite (eg domperidone, cisapride, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)
•Lactose intolerance/other food allergy(ies), including hops allergy, diagnosed idiopathic anaphylaxis or occupational exposure to hops (hops pickers, brewers)
•Current gallbladder or pancreatic disease
•Cardiovascular or respiratory diseases
•Individuals with low ferritin levels (<30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study
•Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above)
•High performance athletes
•Current intake of > 2 standard drinks on > 5 days per week
•Current smokers of cigarettes/cigars/marijuana
•Recreational drug use
•Current intake of any illicit substance
•Vegetarians
•Inability to tolerate nasogastric tube
•Inability to comprehend study protocol
•Restrained eaters (score >12 on the 3-factor eating questionnaire)

发起方

Professor Christine Feinle-Bisset